Office of Prescription Drug Promotion (OPDP) News
Review the latest news from the Office of Prescription Drug Promotion.
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Review the latest news from the Office of Prescription Drug Promotion.
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Approvals
Scope: Regulatory
Related coverage
More related coverage
Recalls of Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan
Get current information about recalls of blood pressure medications
What’s New for Biologics
Latest news from the Center for Biologics Evaluation and Research
Over-The-Counter Monograph Drug User Fee Program (OMUFA)
A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potentia...
eSubmitter Application History
History of all updates to the application software in reverse chronological order by version number